ZA200903489B - Compositions and methods for treating a neoplasm - Google Patents

Compositions and methods for treating a neoplasm

Info

Publication number
ZA200903489B
ZA200903489B ZA200903489A ZA200903489A ZA200903489B ZA 200903489 B ZA200903489 B ZA 200903489B ZA 200903489 A ZA200903489 A ZA 200903489A ZA 200903489 A ZA200903489 A ZA 200903489A ZA 200903489 B ZA200903489 B ZA 200903489B
Authority
ZA
South Africa
Prior art keywords
neoplasm
compositions
treating
methods
Prior art date
Application number
ZA200903489A
Other languages
English (en)
Inventor
Robert D Mass
Gregory D Plowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA200903489B publication Critical patent/ZA200903489B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200903489A 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm ZA200903489B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11

Publications (1)

Publication Number Publication Date
ZA200903489B true ZA200903489B (en) 2010-08-25

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903489A ZA200903489B (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Country Status (17)

Country Link
US (1) US20100086544A1 (enExample)
EP (1) EP2099489B1 (enExample)
JP (1) JP2010512407A (enExample)
KR (1) KR101320198B1 (enExample)
CN (1) CN101547705B (enExample)
AU (1) AU2007333565A1 (enExample)
BR (1) BRPI0717688A2 (enExample)
CA (1) CA2670707A1 (enExample)
DK (1) DK2099489T3 (enExample)
IL (1) IL198852A (enExample)
MX (1) MX2009006202A (enExample)
NZ (1) NZ577058A (enExample)
RU (1) RU2482877C2 (enExample)
SG (1) SG177891A1 (enExample)
SI (1) SI2099489T1 (enExample)
WO (1) WO2008073509A2 (enExample)
ZA (1) ZA200903489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655334B1 (en) * 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN113874369B (zh) 2019-05-31 2024-08-27 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
CN1319090A (zh) * 1998-09-25 2001-10-24 贝林格尔英格海姆法玛公司 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Also Published As

Publication number Publication date
BRPI0717688A2 (pt) 2013-01-22
CN101547705A (zh) 2009-09-30
SI2099489T1 (sl) 2014-09-30
DK2099489T3 (da) 2014-08-18
CA2670707A1 (en) 2008-06-19
EP2099489A2 (en) 2009-09-16
WO2008073509A3 (en) 2009-01-08
JP2010512407A (ja) 2010-04-22
KR101320198B1 (ko) 2013-10-30
NZ577058A (en) 2012-04-27
IL198852A0 (en) 2011-08-01
US20100086544A1 (en) 2010-04-08
WO2008073509A2 (en) 2008-06-19
KR20090087908A (ko) 2009-08-18
SG177891A1 (en) 2012-02-28
RU2482877C2 (ru) 2013-05-27
IL198852A (en) 2013-06-27
HK1131064A1 (en) 2010-01-15
EP2099489B1 (en) 2014-05-21
MX2009006202A (es) 2009-06-22
CN101547705B (zh) 2013-06-12
AU2007333565A1 (en) 2008-06-19
RU2009126588A (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
IL198852A0 (en) Compositions and methods for treating a neoplasm
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
IL193014A0 (en) Methods and compositions for treating schizophrenia
IL227746A0 (en) Methods and compositions for the treatment of cancer
ZA200902860B (en) Compositions and methods for binding sphingosine-1-phosphate
IL198851A0 (en) Methods for treating hypercholesterolemia
ZA200900140B (en) Methods and compositions for treating biofilms
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
GB0906630D0 (en) Compositions and method for hair loss prevention
EP2015765A4 (en) METHODS AND COMPOSITIONS FOR TREATING CONDITIONS
ZA200900243B (en) Methods and composition for treating a material
IL210097A0 (en) Compositions and methods for treating unfluenza
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
MY157996A (en) Desulfurizing coke-water salurry and process for preparation thereof
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
GB0621203D0 (en) PLK inhibitors
PL2132251T3 (pl) Kompozycja i sposób
EP2016706A4 (en) METHOD AND ARRANGEMENT FOR VIRTUAL MEETING
ZA201103961B (en) A composition and a method thereof
GB0625208D0 (en) Composition and method
GB0620930D0 (en) Composition and method for use thereof
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
GB0600261D0 (en) Composition and method